Акции Cue Biopharma упали на 3,8% на фоне роста объема торгов и разнонаправленных оценок аналитиков

Акции биотехнологической компании Cue Biopharma снизились на 3,8% в ходе торгов в понедельник, при этом объем сделки вырос на 85% по сравнению со средним показателем. Несмотря на то, что компания превысила прогнозы по выручке в последнем квартале, консенсус-рейтинг у аналитиков остается «Продать».

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report)’s stock price fell 3.8% during mid-day trading on Monday . The stock traded as low as $24.80 and last traded at $26.10. Approximately 315,940 shares were traded during mid-day trading, an increase of 85% from the average session volume of 170,606 shares. The stock had previously closed at $27.12. Analyst Upgrades and Downgrades CUE has been the topic of several research analyst reports. Wall Street Zen raised shares of Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”. Get Our Latest Stock Analysis on Cue Biopharma Cue Biopharma Price Performance Cue Biopharma (NASDAQ:CUE – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.30) by $2.22. The company had revenue of $5.69 million during the quarter, compared to the consensus estimate of $2.50 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. Institutional Trading of Cue Biopharma Large investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma during the 3rd quarter worth $62,000. Stifel Financial Corp boosted its stake in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after acquiring an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc grew its holdings in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after acquiring an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC grew its holdings in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after acquiring an additional 93,333 shares during the last quarter. 35.04% of the stock is currently owned by institutional investors. About Cue Biopharma Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation. Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies. Recommended Stories Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.